Last reviewed · How we verify
Perioperative NALIRIFOX (liposomal Irinotecan in Combination with Fluorouracil, Leucovorin, and Oxaliplatin) in Resectable Pancreatic Adenocarcinoma: Randomized Phase II Trial
To explore the safety and activity of NALIRIFOX (liposomal irinotecan in combination with fluorouracil, leucovorin, and oxaliplatin) in the perioperative and adjuvant treatment in resectable pancreatic adeneocarcinoma.
Details
| Lead sponsor | Taichung Veterans General Hospital |
|---|---|
| Phase | PHASE2 |
| Status | RECRUITING |
| Enrolment | 84 |
| Start date | Wed Mar 05 2025 00:00:00 GMT+0000 (Coordinated Universal Time) |
| Completion | Sat Feb 05 2028 00:00:00 GMT+0000 (Coordinated Universal Time) |
Conditions
- Resectable Pancreatic Adenocarcinoma
Interventions
- NALIRIFOX
Countries
Taiwan